Cost-Effectiveness of Repository Corticotropin Injection for the Treatment of Acute Exacerbations in Multiple Sclerosis

References

• Cook SD, Dhib-Jalbut S, Dowling P, et al. Use of magnetic resonance imaging as well as clinical disease activity in the clinical classification of multiple sclerosis and assessment of its course: a report from an international CMSC consensus conference, March 5–7, 2010. Int J MS Care. 2012;14(3):105–114. doi:10.7224/1537-2073-14.3.105
   Google Scholar
• National Multiple Sclerosis Society. Treating MS. Available from: https://www.nationalmssociety.org/Treating-MS. Accessed August 7, 2019.
   Google Scholar
• Tullman MJ. Overview of the epidemiology, diagnosis, and disease progression associated with multiple sclerosis. Am J Manag Care. 2013;19(2 Suppl):S15–S20.
   PubMed Web of Science ®Google Scholar
• Hersh C, Fox R. Multiple sclerosis. Available from: http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/neurology/multiple_sclerosis/. Accessed August 7, 2019.
   Google Scholar
• Nazareth TA, Rava AR, Polyakov JL, et al. Relapse prevalence, symptoms, and health care engagement: patient insights from the Multiple Sclerosis in America 2017 survey. Mult Scler Relat Disord. 2018;26:219–234. doi:10.1016/j.msard.2018.09.002
   Web of Science ®Google Scholar
• Mowry EM, Beheshtian A, Waubant E, et al. Quality of life in multiple sclerosis is associated with lesion burden and brain volume measures. Neurology. 2009;72(20):1760–1765. doi:10.1212/WNL.0b013e3181a609f8
   PubMed Web of Science ®Google Scholar
• Berkovich R. Treatment of acute relapses in multiple sclerosis. Neurotherapeutics. 2013;10(1):97–105. doi:10.1007/s13311-012-0160-7
   PubMed Web of Science ®Google Scholar
• Nazareth T, Datar M, Yu TC. Treatment effectiveness for resolution of multiple sclerosis relapse in a US health plan population. Neurol Ther. 2019;8(2):383–395. doi:10.1007/s40120-019-00156-5
   PubMed Web of Science ®Google Scholar
• Cortese I, Chaudhry V, So YT, Cantor F, Cornblath DR, Rae-Grant A. Evidence-based guideline update: plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2011;76(3):294–300. doi:10.1212/WNL.0b013e318207b1f6
   PubMed Web of Science ®Google Scholar
• Weinshenker BG, O’Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol. 1999;46(6):878–886. doi:10.1002/1531-8249(199912)46:6<878::aid-ana10>3.0.co;2-q
   PubMed Web of Science ®Google Scholar
• Lehmann HC, Hartung HP, Hetzel GR, Stuve O, Kieseier BC. Plasma exchange in neuroimmunological disorders: part 1: rationale and treatment of inflammatory central nervous system disorders. Arch Neurol. 2006;63(7):930–935. doi:10.1001/archneur.63.7.930
   PubMedGoogle Scholar
• Elovaara I, Kuusisto H, Wu X, Rinta S, Dastidar P, Reipert B. Intravenous immunoglobulins are a therapeutic option in the treatment of multiple sclerosis relapse. Clin Neuropharmacol. 2011;34(2):84–89. doi:10.1097/WNF.0b013e31820a17f3
   PubMed Web of Science ®Google Scholar
• Soelberg Sorensen P, Haas J, Sellebjerg F, Olsson T, Ravnborg M. IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS. Neurology. 2004;63(11):2028–2033. doi:10.1212/01.wnl.0000145798.61383.39
   Web of Science ®Google Scholar
• Bayry J, Hartung HP, Kaveri SV. IVIg for relapsing-remitting multiple sclerosis: promises and uncertainties. Trends Pharmacol Sci. 2015;36(7):419–421. doi:10.1016/j.tips.2015.04.012
   Web of Science ®Google Scholar
• Mallinckrodt Pharmaceuticals. Acthar^® Gel prescribing information; 2021. Available from: https://www.acthar.com/pdf/Acthar-PI.pdf. Accessed September 23, 2021.
   Google Scholar
• Costello J, Njue A, Lyall M, et al. Efficacy, safety, and quality-of-life of treatments for acute relapses of multiple sclerosis: results from a literature review of randomized controlled trials. Degener Neurol Neuromuscul Dis. 2019;9:55–78. doi:10.2147/DNND.S208815
   Web of Science ®Google Scholar
• Kaplan J, Miller T, Baker M, Due B, Zhao E. Topline results of a prospective observational registry of repository corticotropin injection for the treatment of multiple sclerosis relapse. Multiple Sclerosis J. 2020;26:48–49.
   Web of Science ®Google Scholar
• Nazareth T, Datar M, Sheer R, Yu T, Schwab P. Multiple sclerosis relapse resolution with corticosteroid alternatives: a retrospective claims analysis of us health plan data. Multiple Sclerosis J. 2018;24:900–901.
   Web of Science ®Google Scholar
• Gold LS, Suh K, Schepman PB, Damal K, Hansen RN. Healthcare costs and resource utilization in patients with multiple sclerosis relapses treated with H.P. Acthar Gel®. Adv Ther. 2016;33(8):1279–1292. doi:10.1007/s12325-016-0363-0
   PubMed Web of Science ®Google Scholar
• Wan GJ, Chopra I, Niewoehner J, Hunter SF. Cost per response analysis of repository corticotropin injection versus other alternative treatments for acute exacerbations of multiple sclerosis. Drugs Context. 2020;9:1–7. doi:10.7573/dic.2020-9-4
   Google Scholar
• Oleen-Burkey M, Castelli-Haley J, Lage MJ, Johnson KP. Burden of a multiple sclerosis relapse: the patient’s perspective. Patient. 2012;5(1):57–69. doi:10.2165/11592160-000000000-00000
   PubMedGoogle Scholar
• Ramsey SD, Willke RJ, Glick H, et al. Cost-effectiveness analysis alongside clinical trials II-an ISPOR Good Research Practices Task Force report. Value Health. 2015;18(2):161–172. doi:10.1016/j.jval.2015.02.001
   PubMed Web of Science ®Google Scholar
• Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093–1103. doi:10.1001/jama.2016.12195
   PubMed Web of Science ®Google Scholar
• Sormani MP, Bonzano L, Roccatagliata L, Mancardi GL, Uccelli A, Bruzzi P. Surrogate endpoints for EDSS worsening in multiple sclerosis. A meta-analytic approach. Neurology. 2010;75(4):302–309. doi:10.1212/WNL.0b013e3181ea15aa
   PubMed Web of Science ®Google Scholar
• National Multiple Sclerosis Society. Managing multiple sclerosis: relapse management. Available from: https://www.nationalmssociety.org/For-Professionals/Clinical-Care/Managing-MS/Relapse-Management. Accessed August 12, 2021.
   Google Scholar
• Chastek BJ, Oleen-Burkey M, Lopez-Bresnahan MV. Medical chart validation of an algorithm for identifying multiple sclerosis relapse in healthcare claims. J Med Econ. 2010;13(4):618–625. doi:10.3111/13696998.2010.523670
   PubMedGoogle Scholar
• Heatwole C, Johnson N, Holloway R, Noyes K. Plasma exchange versus intravenous immunoglobulin for myasthenia gravis crisis: an acute hospital cost comparison study. J Clin Neuromuscul Dis. 2011;13(2):85–94. doi:10.1097/CND.0b013e31822c34dd
   PubMedGoogle Scholar
• Mauskopf J, Fay M, Iyer R, Sarda S, Livingston T. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States. J Med Econ. 2016;19(4):432–442. doi:10.3111/13696998.2015.1135805
   PubMed Web of Science ®Google Scholar
• Scalfari A, Neuhaus A, Degenhardt A, et al. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain. 2010;133(7):1914–1929. doi:10.1093/brain/awq118
   PubMed Web of Science ®Google Scholar
• Multiple Sclerosis Trust. Expanded Disability Status Scale (EDSS). Available from: https://www.mstrust.org.uk/a-z/expanded-disability-status-scale-edss. Accessed November 24, 2019.
   Google Scholar
• Kaplan J, Miller T, Baker M, Due B, Zhao E, Wan GJ. Patient-reported outcomes from a prospective observational registry of repository corticotropin injection for the treatment of multiple sclerosis relapse. J Manag Care Special Pharma. 2020;26(4–aSuppl):S42. doi:10.18553/jmcp.2020.26.4-a.s1
   Google Scholar
• Grifols Therapeutics LLC. Gamunex®-C. Available from: https://www.gamunex-c.com/documents/27482625/27482925/Gamunex-C+Prescribing+Information.pdf/9258bd0f-4205-47e1-ab80-540304c1ff8e. Accessed March 18, 2020.
   Google Scholar
• Pilutti LA, Dlugonski D, Pula JH, Motl RW. Weight status in persons with multiple sclerosis: implications for mobility outcomes. J Obes. 2012;2012:868256. doi:10.1155/2012/868256
   PubMedGoogle Scholar
• Cleveland Clinic Mellen Center for Multiple Sclerosis Treatment and Research. Mellen center approaches: IVIG. Available from: https://my.clevelandclinic.org/departments/neurological/depts/multiple-sclerosis/ms-approaches/ivig. Accessed December 18, 2020.
   Google Scholar
• van den Hout WB. The value of productivity: human-capital versus friction-cost method. Ann Rheum Dis. 2010;69(Suppl 1):i89–i91. doi:10.1136/ard.2009.117150
   PubMed Web of Science ®Google Scholar
• Kobelt G, Berg J, Atherly D, Hadjimichael O. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology. 2006;66(11):1696–1702. doi:10.1212/01.wnl.0000218309.01322.5c
   PubMed Web of Science ®Google Scholar
• Wallin MT, Culpepper WJ, Nichols E; Global Burden of Diseases Multiple Sclerosis Collaborators. Global, regional, and national burden of multiple sclerosis 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(3):269–285. doi:10.1016/S1474-4422(18)30443-5
   PubMed Web of Science ®Google Scholar
• Porter ME. What is value in health care? N Engl J Med. 2010;363(26):2477–2481. doi:10.1056/NEJMp1011024
   PubMed Web of Science ®Google Scholar
• Dubois RW. Cost-effectiveness thresholds in the USA: are they coming? Are they already here? J Comp Eff Res. 2016;5(1):9–11. doi:10.2217/cer.15.50
   PubMed Web of Science ®Google Scholar
• Institute for Clinical and Economic Review. 2020–2023 value assessment framework; 2020. Available from: https://icer.org/wp-content/uploads/2020/10/ICER_2020_2023_VAF_013120-4.pdf. Accessed December 10, 2020.
   Google Scholar
• Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness–the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371(9):796–797. doi:10.1056/NEJMp1405158
   PubMed Web of Science ®Google Scholar
• Glanz BI, Degano IR, Rintell DJ, Chitnis T, Weiner HL, Healy BC. Work productivity in relapsing multiple sclerosis: associations with disability, depression, fatigue, anxiety, cognition, and health-related quality of life. Value Health. 2012;15(8):1029–1035. doi:10.1016/j.jval.2012.07.010
   PubMed Web of Science ®Google Scholar
• Kohlmann T, Wang C, Lipinski J, et al. The impact of a patient support program for multiple sclerosis on patient satisfaction and subjective health status. J Neurosci Nurs. 2013;45(3):E3–E14. doi:10.1097/JNN.0b013e31828a4161
   Web of Science ®Google Scholar
• Massetti M, Aballea S, Videau Y, Remuzat C, Roiz J, Toumi M. A comparison of HAS & NICE guidelines for the economic evaluation of health technologies in the context of their respective national health care systems and cultural environments. J Mark Access Health Policy. 2015;3. doi:10.3402/jmahp.v3.24966.
   Google Scholar
• Ernst R. Indirect costs and cost-effectiveness analysis. Value Health. 2006;9(4):253–261. doi:10.1111/j.1524-4733.2006.00114.x
   PubMed Web of Science ®Google Scholar
• Kaplan J, Miller T, Baker M, Due B, Zhao E. A prospective observational registry of repository corticotropin injection (Acthar® Gel) for the treatment of multiple sclerosis relapse. Front Neurol. 2020;11:598496. doi:10.3389/fneur.2020.598496
   PubMed Web of Science ®Google Scholar
• International Business Machines. IBM Micromedex® RED BOOK®. Available from: https://www.micromedexsolutions.com/home/dispatch. Accessed September 23, 2021.
   Google Scholar
• Navarro-Martinez R, Cauli O. Therapeutic plasmapheresis with albumin replacement in Alzheimer’s disease and chronic progressive multiple sclerosis: a review. Pharmaceuticals (Basel). 2020;13(2):28. doi:10.3390/ph13020028
   Google Scholar
• Winters JL, Brown D, Hazard E, Chainani A, Andrzejewski C Jr. Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barre syndrome. BMC Health Serv Res. 2011;11:101. doi:10.1186/1472-6963-11-101
   PubMed Web of Science ®Google Scholar
• Centers for Medicare & Medicaid Services. Physician Fee Schedule. Available from: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeeSched. Accessed March 18, 2020.
   Google Scholar
• Katz U, Kishner I, Magalashvili D, Shoenfeld Y, Achiron A. Long term safety of IVIg therapy in multiple sclerosis: 10 years experience. Autoimmunity. 2006;39(6):513–517. doi:10.1080/08916930600825867
   PubMed Web of Science ®Google Scholar
• Strand V, Shah R, Atzinger C, et al. Economic burden of fatigue or morning stiffness among patients with rheumatoid arthritis: a retrospective analysis from real-world data. Curr Med Res Opin. 2020;36(1):161–168. doi:10.1080/03007995.2019.1658974
   PubMed Web of Science ®Google Scholar
• Hagiwara M, Borker R, Oster G. Economic burden of adverse events in patients with metastatic renal cell carcinoma. Clin Ther. 2013;35(12):1955–1963 e2. doi:10.1016/j.clinthera.2013.10.010
   PubMed Web of Science ®Google Scholar
• O’Brien JA, Ward AJ, Patrick AR, Caro J. Cost of managing an episode of relapse in multiple sclerosis in the United States. BMC Health Serv Res. 2003;3(1):17. doi:10.1186/1472-6963-3-17
   PubMed Web of Science ®Google Scholar
• O’Connell K, Kelly SB, Fogarty E, et al. Economic costs associated with an MS relapse. Mult Scler Relat Disord. 2014;3(6):678–683. doi:10.1016/j.msard.2014.09.002
   Web of Science ®Google Scholar
• Parisé H, Laliberte F, Lefebvre P, et al. Direct and indirect cost burden associated with multiple sclerosis relapses: excess costs of persons with MS and their spouse caregivers. J Neurol Sci. 2013;330(1–2):71–77. doi:10.1016/j.jns.2013.04.007
   PubMed Web of Science ®Google Scholar